Delnova Demonstrates Proof of Concept for ReViVox

Delnova’s ReViVox showed reversal or muscle paralysis or weakness in a small cohort of healthy subjects.

ReViVox is being developed to resolve side effects that may result from botulinum neurotoxin treatments. 

In the proof-of-concept study, volunteer subjects who experienced wrinkle reduction from the neurotoxin treatment were subjected to reversal therapy. Based on a 4-point validated photo-numeric scale, subjects treated with the ReViVox active drug demonstrated recovery in muscle movement as soon as five minutes after treatment. 

This is the first human demonstration of the reversal of muscle weakness caused by a neurotoxin via a local muscle injection.  This study was conducted by Steve Yoelin, MD, an ophthalmologist in Newport. Calif.